STAT+: Medicare’s advisory committee isn’t sold on big pay raises for doctors
On Thursday, the Medicare Payment Advisory Commission reviewed Medicare performance data and concluded that despite…
Category: STAT+
STAT+: A Q&A with the CEO of CRISPR Therapeutics on a historic approval and the road ahead
Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics were all started in the 2013-2014 time frame…
.jpg)
STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote
And so, another working week will soon draw to a close. Not a moment too…
Opinion: STAT+: Health care AI requires a new Hippocratic oath
It was no surprise when the Biden administration recently outlined in a broad executive order…
STAT+: New proposals for scientific misconduct investigations worry some research universities
Research universities are voicing concerns over some proposed changes to the process for reviewing scientific…
STAT+: Sen. Warren pushes for more data on Medicare Advantage coverage hurdles, denials
A bipartisan group of senators is urging the Biden administration to beef up the amount…
STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts
Will this be a half a loaf? After months of deliberation, the Biden administration on…
STAT+: Medtronic cancels $738 million acquisition of diabetes tech company EOFlow
Medtronic is no longer buying EOFlow, a Korean maker of wearable insulin pumps. The news…
STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer…
Sanofi says it has 12 blockbusters in its back pocket. Will investors believe it?
NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their…
STAT+: To lower drug prices, White House takes new aim at pharma patents
WASHINGTON — The White House is throwing its support behind a controversial authority that allows…
STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion
Abbvie announced Wednesday that it will purchase Cereval Therapeutics and its pipeline of experimental neurological…
STAT+: Stephen Hemsley, UnitedHealth Group board chair, sells nearly $113 million in stock
Stephen Hemsley, the board chair and former CEO of UnitedHealth Group, has sold nearly $113…
STAT+: Using Pap smears for earlier ovarian cancer detection shows promise in small new study
Ovarian cancer owes its often-dismal prognosis to the late stage at which it’s typically discovered….
STAT+: Using AI, scientists create blood test that measures organ aging and predicts disease risk
In today’s mostly plague- and famine-free world, if you can avoid more modern scourges like…
STAT+: U.S. judge orders Minnesota to pause its drug pricing transparency law over constitutional issues
In a victory for the pharmaceutical industry, a U.S. judge ruled that Minnesota must temporarily…
STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
Opinion: STAT+: A bold approach to pay for weight loss drugs for everyone who needs them
The news about anti-obesity drugs keeps getting better. In November, data presented at the American…
STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn
CVS Health is promising to simplify how its pharmacies get paid for drugs. But that…
STAT+: Senate panel considers Medicare policy fixes to drug shortages
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using…
STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts
NEW YORK — Will the world actually soon spend $100 billion a year on the…
STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million
Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series…
STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies
Hello, everyone, and how are you today? We are doing just fine, thank you, as…
STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis…
STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to…
STAT+: Cancer drug shortages won’t get better under Biden’s latest plan
WASHINGTON — President Biden’s new plan to curb drug shortages by boosting domestic drug production…
STAT+: Official: FDA needs staff influx to meet gene therapy needs
WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its…
STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds
In the wake of the Covid-19 pandemic, the Food and Drug Administration inspected far fewer…
STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: How sickle cell became the first disease treated by CRISPR
Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of…
STAT+: Roche to acquire obesity-focused Carmot Therapeutics for $2.7 billion
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said…
STAT+: Pharmalittle: Pfizer halts development of twice-daily obesity pill; Supreme Court to review Purdue bankruptcy deal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pfizer to halt development of its twice-daily oral obesity drug, following disappointing trial
Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after…
STAT+: Senate Republicans throw cold water on so-called site-neutral hospital pay cuts
WASHINGTON — On its face, a minor policy to make sure Medicare pays hospitals the…
STAT+: U.S. Supreme Court to review controversial Purdue Pharma bankruptcy settlement
After weeks of anticipation, the U.S. Supreme Court on Monday will hear arguments to decide…
STAT+: Patients wants test results now, and radiologists need time to explain. Can they meet in the middle?
One of the hardest parts about getting an X-ray or a CT scan is the…
STAT+: Texas AG accuses Pfizer of ‘intentionally’ overstating Covid-19 vaccine effectiveness
The Texas attorney general has filed a lawsuit accusing Pfizer of “unlawfully” and “intentionally” misrepresenting…
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion
AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring…
STAT+: Critics say HCA’s cost-cutting is endangering Appalachian patients — a warning for the whole U.S. health care system
ASHEVILLE, N.C. — There was the beeping of monitors, the stiff sheets, the sterile smell…
STAT+: Cigna, Humana in talks to merge into health insurance giant, per report
Cigna and Humana are in discussions to merge, a potential move that would create a…
STAT+: Biden defends Trump-era drug pricing rule on copay accumulators
WASHINGTON — The Biden administration is appealing a court ruling against a Trump-era regulation that…
STAT+: FDA chief scientist to replace Woodcock
WASHINGTON — The Food and Drug Administration’s chief scientist will replace retiring Janet Woodcock as principal…
STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator
The Hevolution Foundation, a Saudi investment firm focused on aging science, said Wednesday that it…
.jpg)
STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases
The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy…
STAT+: Colon cancer prevention paradox: Higher-risk patients pay more for colonoscopy
Ashley Conway-Anderson was prepared for a lot of things when it came to her first…
STAT+: White House official dings Bristol-Myers Squibb for fighting off generic competition
WASHINGTON — A top White House official on Tuesday delivered a pointed attack at a…
STAT+: Scott Gottlieb, Trump FDA chief, questions whether there’s a Republican philosophy on health care
WASHINGTON — One of the Republican party’s most prominent health care thinkers doesn’t know what…